Respiratory Syncytial Virus (RSV) IgM ELISA kit is an enzyme immunoassays (microtiter strips) for the qualitative and quantitative determination of IgM antibodies against Respiratory Syncytial Virus (RSV) in human serum and plasma. Respiratory Syncytial Virus (RSV) IgM ELISA kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The wells of this Respiratory Syncytial Virus (RSV) IgM ELISA kit are coated with antigen. Specific antibodies of the sample binding to the antigen coated wells are detected by a secondary enzyme conjugated antibody (E-Ab) specific for human IgM. After the substrate reaction the intensity of the color developed is proportional to the amount of IgM-specific antibodies detected. Results of samples can be determined directly using the standard curve.
The Respiratory Syncytial Virus (RSV) IgM ELISA kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sunlight. The storage and stability of specimen and prepared reagents is stated in the protocol insert. The microtiter strips of this Respiratory Syncytial Virus (RSV) IgM ELISA kit are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C. The test using this Respiratory Syncytial Virus (RSV) IgM ELISA kit are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards used with this Respiratory Syncytial Virus (RSV) IgM ELISA kit must be found within the acceptable ranges as stated on the QC Certificate. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls.
The most noticible connection of RSV infections with respiratory infections and specific clinical syndromes was detected in infants up to 6 months of age with bronchiolitis or pneumonia. In older infants or small children the disease is milder. In 25% of infections of the respiratory tract RSV infections are detectable. As re-infections with RSV are possible, it is assumed that these pre-infectious antibodies are responsible for the mild course of the disease in adults quite similar to a cold. However, especially in the early years, serum antibodies lead not to an effective protection against infections of the respiratory tract. Therefore, this pathogen may cause bronchiolitis or in infants up to 4 months of age pneumonias. Based on their antigen relationship, RSV isolates can be differentiated into two major groups (A and B). The surface glycoproteins of the virus (the G glycoprotein and the fusion glycoprotein) cause the production of virus-neutralizing antibodies. Obviously the G glycoproteins of groups A and B are very different in comparison to the F glycoproteins. The complement binding reaction is unsatisfactory for the serological diagnosis of RSV. Enzyme immunoassays are of higher diagnostic value for the serological diagnosis of RSV infections, as they are very sensitive and allow the differentiation of antigens into the various immunoglobulin classes. In RSV infections, it is possible that the IgM antibody response is missing or so weak that a reliable interpretation of the results is impossible. The detection of IgG antibodies in a single sample is no evidence for an acute infection as IgA antibodies may persist months and years. The method recommended for serological testing of acute RSV infections is the determination of IgG antibodies in serum pairs with a significant titer rise.
Download Product Data Sheet